Provided by Tiger Trade Technology Pte. Ltd.

Connect Biopharma Holdings Ltd.

0.9797
-0.1203-10.94%
Post-market: 0.9778-0.0019-0.19%18:40 EDT
Volume:7.93M
Turnover:8.11M
Market Cap:61.69M
PE:-0.82
High:1.12
Open:1.12
Low:0.9433
Close:1.10
52wk High:3.82
52wk Low:0.9433
Shares:62.96M
Float Shares:21.58M
Volume Ratio:0.23
T/O Rate:36.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1933
EPS(LYR):-1.0000
ROE:-140.51%
ROA:-69.75%
PB:2.30
PE(LYR):-0.98

Loading ...

3 Penny Stocks on Investors’ Radar, October 1

TIPRANKS
·
Yesterday

US Research Roundup-Amrize, Dexcom, Lennar

Reuters
·
Yesterday

Connect Biopharma Holdings Ltd : Btig Cuts Target Price to $5 from $10

THOMSON REUTERS
·
Yesterday

NASD Most Active Issues

Dow Jones
·
Yesterday

Top Midday Gainers

MT Newswires Live
·
Yesterday

Lake Street Sticks to Its Buy Rating for Connect Biopharma Holdings (CNTB)

TIPRANKS
·
Sep 30

Why Is Penny Stock Connect Biopharma (CNTB) Up 98% Today?

TIPRANKS
·
Sep 30

Connect Biopharma reports positive Phase 2 COPD results

TIPRANKS
·
Sep 30

Connect Biopharma announces results from global Phase 2 study of rademikibart

TIPRANKS
·
Sep 30

Connect Biopharma Says Phase 2 Trial Shows Rademikibart Cuts COPD Treatment Failure Rate 81% Through Week 4

Reuters
·
Sep 30

Connect Biopharma - Rademikibart Reduced Treatment Failure Rate by 81% Through One Month in Phase 2 Study

THOMSON REUTERS
·
Sep 30

Connect Biopharma - to Engage FDA for Phase 3 Program for Rademikibart in Copd

THOMSON REUTERS
·
Sep 30

Connect Biopharma Announces Positive Preliminary Topline Data from Its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with Copd and Type 2 Inflammation

THOMSON REUTERS
·
Sep 30

Connect Biopharma - Rademikibart Reduced Hospitalizations or Ed Visits for Acute Copd Exacerbations by 100%

THOMSON REUTERS
·
Sep 30

Connect Biopharma - Rademikibart Well Tolerated with Lower Incidence of Adverse Events than Placebo

THOMSON REUTERS
·
Sep 30

Connect Biopharma price target lowered to $5 from $8 at Oppenheimer

TIPRANKS
·
Sep 22

US Research Roundup-Boeing, Twilio, WP Carey

Reuters
·
Sep 22

H.C. Wainwright Sticks to Its Buy Rating for Connect Biopharma Holdings (CNTB)

TIPRANKS
·
Sep 22

Connect Biopharma Price Target Maintained with a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 17

Connect Biopharma price target lowered to $6 from $7 at Canaccord

TIPRANKS
·
Sep 16